𝔖 Bobbio Scriptorium
✦   LIBER   ✦

BROMOCRIPTINE VERSUS PLACEBO IN LEVODOPA TREATED PATIENTS WITH PARKINSON'S DISEASE

✍ Scribed by Ulla Grøn

Book ID
114780615
Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
234 KB
Volume
56
Category
Article
ISSN
0001-6314

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cysteine elevation in levodopa-treated p
Cysteine elevation in levodopa-treated patients with Parkinson's disease
✍ Thomas Müller; Wilfried Kuhn 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 305 KB 👁 1 views

## Abstract Homocysteine, cysteine, and cysteinyl‐glycine are all metabolically interrelated. Levodopa/decarboxylase inhibitor (LD/DCI) administration increases total homocysteine (tHcy) plasma levels. Objectives were to investigate associations between LD/DCI intake, concentrations of tHcy, cystei

Hyperhomocysteinemia in levodopa-treated
Hyperhomocysteinemia in levodopa-treated patients with Parkinson's disease dementia
✍ Stefano Zoccolella; Claudia dell'Aquila; Giovanni Abruzzese; Angelo Antonini; Ub 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 78 KB

## Abstract Dementia is a frequent non‐motor feature of Parkinson's disease (PD). Elevated plasma homocysteine (Hcy) levels have been associated with both cognitive impairment and dementia. Increased Hcy levels have been observed in levodopa‐treated patients with PD. The objective of our study was

Mortality of patients with parkinson's d
Mortality of patients with parkinson's disease treated with levodopa
✍ R. J. Marttila; U. K. Rinne; T. Siirtola; V. Sonninen 📂 Article 📅 1977 🏛 Springer 🌐 English ⚖ 372 KB

The effect of levodopa on the mortality of patients with Parkinson's disease was investigated in 349 patients treated with levodopa or levodopa combined with decarboxylase inhibitor during 1969-1975 inclusive. During the study period, 61 patients died. The expected mortality was 32.99 resulting in a